Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$13.72
+0.16 (+1.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $506.2M · quality 84.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.1B
P/E
17.8x
↓EV/EBITDA
11.5x
↓ROE
13.6%
↑Gross Margin
76.0%
↑Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
+10.0%
FCF margin
30.4%
FCF / Net income
1.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.05B · net income $433.1M · FCF $621.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.05B | $2.05B | $2.19B | $2.17B | $1.96B |
| Net Income | $433.1M | $433.1M | $521.5M | $421.3M | $329.5M |
| EBITDA | $656.1M | $656.1M | $767.9M | $649.8M | $581.2M |
| EPS | 0.74 | 0.74 | 0.89 | 0.72 | 0.56 |
| Gross Margin | 76.0% | 76.0% | 73.4% | 73.0% | 71.0% |
| Operating Margin | 27.8% | 27.8% | 26.1% | 23.7% | 20.8% |
| Net Margin | 21.2% | 21.2% | 23.8% | 19.4% | 16.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.20 | 0.19 | 0.17 |
| Current Ratio | 3.97 | 3.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $621.2M | $621.2M | $506.2M | $472.9M | $466.4M |
| Returns | |||||
| ROE | 13.6% | 13.6% | 17.3% | 15.0% | 11.7% |
| Valuation | |||||
| P/E | 17.82 | 17.82 | 17.39 | 20.22 | 23.87 |
| EV/EBITDA | 11.51 | 11.51 | 11.22 | 12.30 | 12.16 |
| P/B | 2.52 | 2.52 | 3.01 | 3.02 | 2.80 |
| Growth & Yield | |||||
| Revenue Growth | -6.8% | -6.8% | 1.0% | 10.8% | — |
| EPS Growth | -16.9% | -16.9% | 23.6% | 28.6% | — |
| Dividend Yield | 3.6% | 3.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.1%
EPS terminal req.
$1.22
Spread vs growth
-34.9%
5Y implied EPS CAGR
14.8%
EPS terminal req.
$1.47
Spread vs growth
-31.6%
10Y implied EPS CAGR
12.4%
EPS terminal req.
$2.37
Spread vs growth
-29.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.0%
Start / end P/E
16.0x → 18.5x
EPS bridge
0.89 → 0.74
Residual
-2.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.